DocGo (DCGO) Free Cash Flow Analysis: A Mobile Health Startup Reaching FCF Profitability

FCF Performance Summary

Note: Revenue approximately $648M in FY2024 (derived from 10.8% FCF margin on reported FCF). FY2021 OCF rounds to near zero. CapEx figures are rounded; the model is capital-light with minimal fixed asset investment.

FCF Quality Score: 6/10

DocGo is one of the few companies in this series where the FCF quality score is explicitly limited by a short and volatile track record. CapEx consistently runs below $10M, practically irrelevant relative to operating cash flow, so FCF and OCF are nearly identical. The real driver of year-to-year FCF swings is working capital: FY2024's OCF/NI ratio of 350% reflects a large working capital recovery after FY2023's cash burn, not sustained structural quality. The 83.7% FCF yield and 1.2x P/FCF don't signal undervaluation. They signal the market's legitimate skepticism about whether $70M in FY2024 FCF is the start of a durable pattern or just a bounce from a trough year.

4-Year FCF Trend Analysis

Free Cash Flow Trajectory: High Volatility

FY 2021:  -$10M ──┐ (SPAC IPO year; growth investment, ramp costs)
FY 2022:  +$30M   │ ← First positive year; early traction
FY 2023:  -$70M   │ ← Sharp reversal; working capital deterioration
FY 2024:  +$70M ──┘ ← Recovery; strongest FCF result to date

DocGo's four-year FCF history alternates between positive and negative results: FY2022 (+$30M), FY2023 (-$70M), FY2024 (+$70M). That oscillation shows just how dependent FCF is on working capital management in any given year. FY2021, the SPAC IPO year, produced minimal negative FCF as the company absorbed early-stage ramp costs; revenue was small and the business was still building operational infrastructure. FY2022 brought the company's first sustained positive FCF year, $30M, supported by rapid revenue growth in public health and transport programs. Then came the FY2023 reversal: FCF collapsed to -$70M. The most likely drivers include rapid headcount and capacity build-out for large public health contracts such as migrant health services, the timing of receivables collection on government-funded programs, and operating expenses that outpaced collections. That reversal is the defining risk factor in DocGo's profile. FY2024 brought recovery: FCF returned to +$70M, matching FY2023's negative magnitude with the opposite sign. The 350% OCF/NI ratio points to a substantial working capital recovery, better payables management and improved receivables collection, rather than purely income-driven FCF growth.

Operating Cash Flow: Mirrors FCF (Capital-Light)

Because CapEx is negligible, OCF and FCF are effectively synonymous for DocGo. The company's FCF trajectory is therefore a near-direct read on its operating cash generation. The capital-light nature of the mobile health model, no owned hospitals, limited owned vehicles in some programs, minimal physical infrastructure, is both a structural advantage and the reason why all FCF risk is concentrated in operating working capital rather than investment spending.

Cash Flow Components Deep Dive

Operating Cash Flow vs. Net Income

Capital Expenditures: Minimal (True Capital-Light Model)

DocGo's capital-light model is one of its defining financial characteristics. Mobile health services, especially transport, field medical teams, and workforce health programs, do not require owned hospitals, MRI machines, or major real estate. The company's infrastructure is primarily technology platforms, personnel networks, and operational coordination systems, none of which require massive capital spending. That's a structural positive for FCF conversion: when OCF is positive, nearly all of it flows through to FCF. The flip side is that CapEx cannot be used to "explain away" negative FCF years. When FCF is negative, it is purely an operating cash flow problem, not an investment cycle explanation.

For a broader discussion of why capital intensity matters in FCF analysis across different industries, see our sector comparison: Industries Where FCF Yield Is Most Relevant.

Capital Allocation: Minimal Activity

DocGo's capital allocation in FY2024 was minimal and straightforward. The $10M buyback program is notable as a signal: management initiated repurchases during a year of positive FCF, suggesting some confidence in the sustainability of the FY2024 result. Still, $10M represents approximately 14% of FY2024 FCF of $70M, so the program is modest in scale and didn't materially impair balance sheet flexibility.

The absence of a dividend is entirely consistent with DocGo's profile: a small-cap growth-oriented company generating its first meaningful positive FCF should prioritize balance sheet strength and operational reinvestment over distributions. A dividend initiation at this stage would be premature given the FCF volatility history. For context on how dividends relate to FCF quality frameworks, see our foundational piece: Why Free Cash Flow Is King.

FCF Quality Score: 6/10 — Mixed With Improving Trajectory

What's Working

DocGo's capital-light business model is the clearest structural strength: with CapEx consistently below $10M, FCF conversion from OCF runs at nearly 100%, meaning cash generated by operations flows directly to FCF without large reinvestment requirements, a real advantage relative to capital-intensive healthcare peers such as hospital operators or medical device manufacturers. The FY2024 result itself is a milestone. $70M in FCF is the strongest result in DocGo's public history and the first year where FCF clearly and materially exceeded zero; a 10.8% FCF margin on ~$648M in revenue is respectable for a healthcare services business, though it needs to repeat across multiple periods before it counts as a durable track record. The 350% OCF/NI ratio in FY2024 reflects a meaningful improvement in collections and payables management, and if the operational changes behind it are structural (better contract management, faster billing cycles, improved receivables processes), they represent genuine FCF quality enhancement rather than a one-time bounce. Stock-based compensation, at roughly $10M and about 1.5% of revenue, is modest, limiting dilution and preserving per-share FCF quality at a company where SBC can otherwise become a meaningful drag on true economic earnings.

Where the Volatility Comes From

The volatile FCF history is the biggest concern in this profile: two of four years produced negative FCF, and the FY2023 swing to -$70M came just one year after a positive $30M result. That level of year-to-year variability is hard to model and suggests the business has not yet reached stable FCF generation, a threshold that matters for establishing genuine FCF quality (our guide on assessing FCF quality explores what that threshold looks like). Because CapEx is minimal, essentially all of that risk is concentrated in working capital. Government and public health contracts, which likely represent a sizable share of DocGo's revenue, carry unpredictable payment timing, receivables aging, and contract termination or modification risk, and the FY2023 reversal appears to reflect this exposure directly. The valuation metrics themselves raise a flag: an 83.7% FCF yield and 1.2x P/FCF would signal deep undervaluation in an established cash-generative business, but for DocGo they more plausibly reflect market skepticism, the market pricing in a real probability that FY2024's positive FCF won't repeat at the same magnitude, a skepticism that the four-year history doesn't make unreasonable. There's also the simple matter of limited history: only four years of public data since the SPAC merger make it hard to separate cyclical FCF patterns from structural ones, and a more complete assessment would need at least 6–8 years across different operating environments. Finally, mobile health companies including DocGo have historically drawn a large share of revenue from government-funded contracts spanning city, state, and federal health programs; these are subject to political budget cycles, public health emergency timelines, and competitive procurement processes, any of which can cause sudden revenue disruptions with direct FCF consequences.

FCF Quality Assessment Summary: DocGo displays mixed FCF characteristics with an improving trajectory. The capital-light model, FY2024 milestone, and working capital recovery are genuine positives. The volatile history, working capital concentration risk, and limited data create meaningful uncertainty. A score of 6/10 reflects the balance: better than the pre-FY2024 profile would suggest, but not yet the profile of a reliable FCF generator.

Forward Outlook & Scenario Analysis

The central question for DocGo's FCF profile is whether FY2024's $70M result represents a new baseline, or a recovery year that will again reverse in FY2025 and beyond. Three scenarios illustrate the range of plausible outcomes:

What Would Confirm a Durable Trend

Accounts receivable and days sales outstanding are the single most important metric to track here: improving DSO would signal structural working capital improvement, while deteriorating DSO is the early warning sign for another FCF reversal, and quarterly 10-Q filings provide the balance sheet data needed to follow it. Government contract renewals and pipeline matter too, since DocGo's exposure to government health programs creates lumpy, contract-driven revenue, and the status of existing large contracts along with the pipeline of new public health program bids is material to forecasting FCF. Movement toward private-sector workforce health programs, such as employer health services and corporate medical programs, would reduce government contract concentration risk and potentially improve receivables predictability. SBC trajectory is worth watching: at $10M in FY2024 it's modest, but if management leans on equity compensation more heavily to retain talent as the company scales, it could become a more meaningful drag on true FCF quality, which makes the SBC-to-revenue ratio worth monitoring across future periods. Operating leverage evidence would help too. If revenue grows and net income margin expands meaningfully above the roughly 3% FY2024 GAAP level, that would be evidence the mobile health model has genuine operating leverage, a prerequisite for durable FCF expansion. And the buyback program itself is a signal: continuing or expanding the $10M repurchase in subsequent periods would indicate sustained confidence in FCF generation, while a halt or suspension would point the other way.

Conclusion

DocGo (DCGO) displays mixed FCF characteristics with an improving trajectory: FY2024's $70M FCF and 10.8% margin represent a genuine operational milestone for the company, but the volatile 4-year history, including two negative FCF years, a sharp FY2023 reversal, and extreme valuation metrics (83.7% FCF yield, 1.2x P/FCF) that reflect market skepticism about sustainability, means FY2024 cannot yet be characterized as the establishment of a durable FCF profile.

DocGo's FCF story is fundamentally about whether a capital-light mobile health operator can translate its operational model into consistent, repeatable cash generation. The structural advantages are real: near-zero CapEx, a scalable service delivery model, and demonstrated ability to generate positive OCF in favorable years. The challenges are equally real: working capital concentration risk, government contract dependency, limited public history, and a FCF pattern that has reversed sharply within single years.

The 350% OCF/NI ratio in FY2024 is worth examining carefully. Unlike large-cap businesses where this ratio is driven by stable D&A on large asset bases, DocGo's gap reflects working capital recovery, a less durable source of OCF quality. If FY2024's improvement reflects genuine process improvements in billing, collections, and contract management, the trajectory is encouraging. If it primarily reflects timing and reversal of FY2023's extraordinary deterioration, the pattern may be mean-reverting rather than structurally improving. Future quarters' cash flow statements will be the primary arbiter of this question.

For a deeper understanding of how to evaluate FCF consistency and quality signals across different business types, see our comprehensive framework: Assessing FCF Quality. For context on how DocGo's capital-light mobile health model compares to capital-intensive healthcare peers in FCF generation, see: Industries Where FCF Yield Is Most Relevant.

Disclaimer: This analysis is for educational and informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of financial recommendation. Nothing in this analysis should be interpreted as a recommendation to buy, sell, or hold any security or financial instrument. The author and FreeCashFlow.org are not licensed financial advisors or registered investment advisors. All financial data is derived from publicly available SEC filings and third-party data sources; accuracy is not guaranteed. You should conduct your own independent research and consult with a licensed financial professional before making any investment decisions. Past performance of any company's FCF or stock price does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources: SEC Edgar XBRL filings (10-K annual reports FY 2021–2024), Stock Analysis (stockanalysis.com), DocGo Inc. annual reports
Methodology: Direct extraction from annual cash flow statements; FCF calculated as Operating Cash Flow minus Capital Expenditures; margin percentages derived from reported revenue; FY2024 revenue estimated from FCF and margin data where not directly cited